ATE285251T1 - Antagoniste des vasculären endothelzellewachstumfaktors - Google Patents

Antagoniste des vasculären endothelzellewachstumfaktors

Info

Publication number
ATE285251T1
ATE285251T1 AT96910651T AT96910651T ATE285251T1 AT E285251 T1 ATE285251 T1 AT E285251T1 AT 96910651 T AT96910651 T AT 96910651T AT 96910651 T AT96910651 T AT 96910651T AT E285251 T1 ATE285251 T1 AT E285251T1
Authority
AT
Austria
Prior art keywords
growth factor
cell growth
vascular endothelial
endothelial cell
antagonist
Prior art date
Application number
AT96910651T
Other languages
English (en)
Inventor
Napoleone Ferrara
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23636728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE285251(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE285251T1 publication Critical patent/ATE285251T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96910651T 1995-03-30 1996-03-28 Antagoniste des vasculären endothelzellewachstumfaktors ATE285251T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41330595A 1995-03-30 1995-03-30
PCT/US1996/004338 WO1996030046A1 (en) 1995-03-30 1996-03-28 Vascular endothelial cell growth factor antagonists

Publications (1)

Publication Number Publication Date
ATE285251T1 true ATE285251T1 (de) 2005-01-15

Family

ID=23636728

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04026995T ATE311902T1 (de) 1995-03-30 1996-03-28 Antagonisten des vaskulären endothelzellen- wachstumfaktors
AT96910651T ATE285251T1 (de) 1995-03-30 1996-03-28 Antagoniste des vasculären endothelzellewachstumfaktors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04026995T ATE311902T1 (de) 1995-03-30 1996-03-28 Antagonisten des vaskulären endothelzellen- wachstumfaktors

Country Status (14)

Country Link
US (8) US20070253959A1 (de)
EP (3) EP1506787B1 (de)
JP (1) JPH11502853A (de)
AT (2) ATE311902T1 (de)
AU (1) AU696487B2 (de)
CA (3) CA2754887A1 (de)
DE (2) DE69634079T2 (de)
DK (1) DK0817648T3 (de)
ES (2) ES2255027T3 (de)
IL (1) IL117645A (de)
MX (1) MX9706828A (de)
NZ (1) NZ305699A (de)
PT (1) PT817648E (de)
WO (1) WO1996030046A1 (de)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE19744531A1 (de) * 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
IL137649A (en) * 1998-02-18 2004-08-31 Genentech Inc Method of adsorption chromatography
PT2016951E (pt) 1998-03-17 2012-09-27 Genentech Inc Polipéptidos homólogos de vegf e de bmp1
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
DE10008946C1 (de) 2000-02-25 2001-10-18 Basf Coatings Ag Verfahren zur Herstellung farb- und/oder effektgebender Mehrschichtlackierungen auf Automobilkarosserien
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
DE10043405C1 (de) 2000-09-04 2002-06-27 Basf Coatings Ag Verfahren zur Herstellung farb- und/oder effektgebender Lackierungen
DE10130972C1 (de) 2001-06-27 2002-11-07 Basf Coatings Ag Verfahren zur Herstellung von Beschichtungen aus thermisch und mit aktinischer Strahlung härtbaren Beschichtungsstoffen und mit dem Verfahren herstellbare Lackierungen
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
AU2002306251A1 (en) * 2002-02-15 2003-09-04 Richard Brunner 7s immunoglobulin for treatment of choroidal neovascularisation_
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
DE102004027650A1 (de) 2004-06-05 2006-01-05 Basf Coatings Ag Verfahren zum Beschichten elektrisch leitfähiger Substrate
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
PT1771474E (pt) 2004-07-20 2010-05-03 Genentech Inc Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
RS52539B (sr) 2004-10-21 2013-04-30 Genentech Inc. Metod za tretiranje intraokularnih neovaskularnih bolesti
CN101184776B (zh) 2005-03-24 2013-04-24 斯路姆基因公司 新型抗胎盘生长因子抗体
US20070025957A1 (en) * 2005-04-29 2007-02-01 Rosenblum Michael G Vascular targeting of ocular neovascularization
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
SI1973950T1 (sl) 2006-01-05 2015-01-30 Genentech, Inc. Anti-EphB4 protitelesa in postopki njihove uporabe
KR101459160B1 (ko) 2006-01-20 2014-11-19 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
CA2654000A1 (en) 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
KR20150072458A (ko) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
HUE029445T2 (en) 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
MX2009007632A (es) 2007-01-22 2009-07-24 Genentech Inc Precipitacion de polielectrolito y purificacion de proteinas.
US8648173B2 (en) 2007-05-17 2014-02-11 Genentech, Inc. Inhibition of tumor metastasis by anti neuropilin 2 antibodies
JP2010530359A (ja) 2007-05-17 2010-09-09 ジェネンテック， インコーポレイテッド ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
CL2008003302A1 (es) 2007-11-09 2009-03-06 Genentech Inc Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
CN102149724B (zh) 2008-08-14 2014-04-09 健泰科生物技术公司 使用原地蛋白质置换离子交换膜层析清除污染物的方法
CA2734275A1 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
MX2011003428A (es) 2008-10-02 2011-07-29 Vib Vzw Inhibicion del factor de crecimiento placentario (plgf) para tratar la leucemia con cromosoma filadelfia positivo.
EP3524620A1 (de) 2008-10-14 2019-08-14 Genentech, Inc. Immunglobulinvarianten und ihre verwendung
EP2358746B1 (de) 2008-11-03 2020-09-16 Molecular Partners AG Bindungsproteine zum hemmen der vegf-a-rezeptorinteraktion
AR074203A1 (es) 2008-11-22 2010-12-29 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
CN102257122B (zh) 2008-12-16 2015-07-29 Emd密理博公司 搅拌槽反应器及方法
JP5416221B2 (ja) 2008-12-23 2014-02-12 ジェネンテック， インコーポレイテッド 癌患者における診断用途のための方法および組成物
CN102333548B (zh) 2009-02-27 2013-01-30 健泰科生物技术公司 用于蛋白质标记的方法和组合物
CN102875677A (zh) 2009-05-08 2013-01-16 霍夫曼-拉罗奇有限公司 人源化抗egfl7抗体及其使用方法
US8933297B2 (en) 2009-06-15 2015-01-13 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in xylosyltransferase activity
BR112012000735A2 (pt) 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
BR112012002974B1 (pt) 2009-08-11 2022-06-07 Genentech, Inc Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
BR112012003346A2 (pt) 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
KR101764449B1 (ko) 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
CN102597776A (zh) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 鉴定响应抗癌剂的可能性升高的患者的方法
JP5606537B2 (ja) 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における診断使用のための方法及び組成物
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
EP2509626B1 (de) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
JP5852010B2 (ja) 2009-12-23 2016-02-03 ジェネンテック， インコーポレイテッド 抗Ｂｖ８抗体およびその使用
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CN110227154A (zh) 2010-02-23 2019-09-13 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Kirin Co., Ltd. Modified antibody composition
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2012151500A (ru) 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
DK2571903T3 (da) 2010-05-17 2019-11-04 Emd Millipore Corp Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
CN103109189A (zh) 2010-07-19 2013-05-15 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
BR112013001433A2 (pt) 2010-07-19 2016-05-31 Hoffmann La Roche método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
JPWO2012017925A1 (ja) 2010-08-02 2013-10-03 協和発酵キリン株式会社 物質の製造方法
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
NZ610487A (en) 2010-11-15 2015-03-27 Five Prime Therapeutics Inc Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
CN103261414A (zh) 2010-12-15 2013-08-21 大学共同利用机关法人情报·系统研究机构 蛋白质的生产方法
WO2012091023A1 (ja) 2010-12-27 2012-07-05 協和発酵キリン株式会社 培地およびキレート剤を含む水溶液の調製方法
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN108178789B (zh) 2011-04-20 2021-11-02 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
EP2551348B1 (de) 2011-07-29 2014-09-24 Icon Genetics GmbH Produktion von galactosylierten N-Glycanen in Pflanzen
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
AU2012320847B2 (en) 2011-10-04 2018-03-08 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
EP2785739B1 (de) 2011-12-01 2017-03-15 ThromboGenics N.V. Verbesserung eines augendrucksenkungsergebnisses
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
BR112014018964A2 (pt) 2012-03-13 2020-05-12 F. Hoffmann-La Roche Ag Anticorpo anti-vegf e uso de um anticorpo anti-vegf
SG10202007206WA (en) 2012-03-27 2020-08-28 Genentech Inc Improved harvest operations for recombinant proteins
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
EP2872534B1 (de) 2012-07-13 2018-08-08 Roche Glycart AG Bispezifische anti-vegf-/anti-ang-2-antikörper und ihre verwendung bei der behandlung von vaskulären augenerkrankungen
SG11201500903XA (en) 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
ES2780674T3 (es) 2012-11-15 2020-08-26 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
BR112015029145A2 (pt) 2013-05-23 2017-09-19 Glaxosmithkline Ip No 2 Ltd Usos de um domínio extracelular (ecd) de receptor de fator de crescimento de fibroblastos 1 (fgfr1) e métodos de identificação de pacientes
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
EP3851118A1 (de) 2013-10-25 2021-07-21 Acceleron Pharma Inc. Endoglinpeptide zur behandlung fibrotischer erkrankungen
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP3828202A1 (de) 2014-05-12 2021-06-02 Formycon AG Vorgefüllte spritze aus kunststoff mit einem vegf-antagonisten
EP3166401B1 (de) 2014-07-09 2020-08-19 F. Hoffmann-La Roche AG Ph-einstellung zur verbesserung der auftaurückgewinnung von zellbänken
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CA2957717C (en) 2014-08-12 2021-10-19 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
EP3191126B1 (de) 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
EP3662903A3 (de) 2014-10-03 2020-10-14 Novartis AG Kombinationstherapien
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
MX2017006864A (es) 2014-12-23 2017-08-28 Genentech Inc Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
NZ741780A (en) 2015-10-30 2019-11-29 Genentech Inc Anti-htra1 antibodies and methods of use thereof
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
CN108883172A (zh) 2015-11-18 2018-11-23 福迈康股份公司 包含vegf拮抗剂的液体配制品的预填充药物包装
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
RU2751510C2 (ru) 2015-11-18 2021-07-14 Сио2 Медикал Продактс, Инк. Фармацевтическая упаковка для офтальмологических составов
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
KR20190012145A (ko) 2016-03-29 2019-02-08 젤터, 인코포레이티드 주변세포질 부피 대 세포질 부피의 비가 0.5:1 내지 10:1인 그람-음성 박테리아에서의 단백질의 발현
CA3019921A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
EP3443120A2 (de) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Verfahren zur überwachung und behandlung von krebs
CN109690315A (zh) 2016-07-08 2019-04-26 豪夫迈·罗氏有限公司 人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
EP3481963B1 (de) 2016-07-08 2025-10-29 Genentech, Inc. Methoden zur diagnose und behandlung von krebs durch bestimmung des expressionsstatus und mutatonsstatus von nrf2 sowie downstream genen von nrf2.
BR112019002036A2 (pt) 2016-08-12 2019-05-14 Genentech Inc métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019254237B2 (en) 2018-04-16 2025-01-30 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
PE20211916A1 (es) 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP4368699A3 (de) 2018-07-03 2024-09-11 Bristol-Myers Squibb Company Verfahren zur herstellung rekombinanter proteine
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
EP3867646A1 (de) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
JP7453151B2 (ja) 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
GB2597416A (en) 2019-04-12 2022-01-26 Geltor Inc Recombinant elastin and production thereof
CN113747944A (zh) 2019-04-19 2021-12-03 詹森生物科技公司 用抗psma/cd3抗体治疗前列腺癌的方法
TWI879768B (zh) 2019-05-03 2025-04-11 美商建南德克公司 用抗pd-l1抗體治療癌症之方法
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
JP7558272B2 (ja) 2019-11-19 2024-09-30 プロタリクス リミテッド 形質転換細胞からの構築物の除去
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4127724A1 (de) 2020-04-03 2023-02-08 Genentech, Inc. Therapeutische und diagnostische verfahren für krebs
JP2023531537A (ja) 2020-06-30 2023-07-24 メンドゥス・ベスローテン・フェンノートシャップ 卵巣癌ワクチンでの白血病由来細胞の使用
JP7808097B2 (ja) 2020-09-22 2026-01-28 ブリストル－マイヤーズ スクイブ カンパニー 治療タンパク質を生産するための方法
EP4225902A1 (de) 2020-10-05 2023-08-16 Protalix Ltd. Würfelförmige knockout-pflanzenzellen
JP2023550028A (ja) 2020-11-13 2023-11-30 ジェネンテック， インコーポレイテッド 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｖｅｇｆ阻害剤を含む方法及び組成物
EP4281102A1 (de) 2021-01-22 2023-11-29 Mendus B.V. Verfahren zur tumorimpfung
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4330436A1 (de) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutische und diagnostische verfahren und zusammensetzungen gegen krebs
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
CA3224180A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023142996A1 (zh) 2022-01-28 2023-08-03 上海岸阔医药科技有限公司 预防或治疗与抗肿瘤剂相关的疾病或病症的方法
KR20240150493A (ko) 2022-02-21 2024-10-15 온퀄리티 파마슈티컬스 차이나 리미티드 화합물 및 그 용도
AU2023260823A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5185438A (en) * 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
EP0666868B2 (de) * 1992-10-28 2006-06-14 Genentech, Inc. Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy

Also Published As

Publication number Publication date
US20110287024A1 (en) 2011-11-24
EP0817648B1 (de) 2004-12-22
US20080181900A1 (en) 2008-07-31
MX9706828A (es) 1997-11-29
EP0817648A1 (de) 1998-01-14
NZ305699A (en) 2000-02-28
AU5378796A (en) 1996-10-16
US20140377276A1 (en) 2014-12-25
DE69634079T2 (de) 2006-01-19
EP1627643A2 (de) 2006-02-22
CA2213833A1 (en) 1996-10-03
EP1506787B1 (de) 2005-12-07
EP1506787A1 (de) 2005-02-16
CA2754887A1 (en) 1996-10-03
IL117645A (en) 2005-08-31
IL117645A0 (en) 1996-07-23
US20100119523A1 (en) 2010-05-13
CA2213833C (en) 2011-10-18
PT817648E (pt) 2005-04-29
EP1627643A3 (de) 2013-06-26
ES2255027T3 (es) 2006-06-16
AU696487B2 (en) 1998-09-10
US20100316652A1 (en) 2010-12-16
ATE311902T1 (de) 2005-12-15
DE69635565T2 (de) 2006-07-27
WO1996030046A1 (en) 1996-10-03
DK0817648T3 (da) 2005-04-04
US20070253959A1 (en) 2007-11-01
JPH11502853A (ja) 1999-03-09
ES2233967T3 (es) 2005-06-16
DE69635565D1 (de) 2006-01-12
CA2805588A1 (en) 1996-10-03
US20130028911A1 (en) 2013-01-31
US20090169556A1 (en) 2009-07-02
DE69634079D1 (de) 2005-01-27

Similar Documents

Publication Publication Date Title
ATE285251T1 (de) Antagoniste des vasculären endothelzellewachstumfaktors
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ES2173873T3 (es) Utilizacion de anticuerpos anti-vegf para el tratammiento del cancer.
IS6922A (is) Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum
EP1385864A4 (de) Vaskulärer endothelwachstumsfaktor 2
ATE235917T1 (de) Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ATE342262T1 (de) Neue integrin rezeptor antagonisten
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE69720241D1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
WO2004091646A3 (en) Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0817648

Country of ref document: EP